Rapid Eye Movement Sleep Behavior Disorder
Management of rapid eye movement sleep behavior disorder (RBD) includes reducing injurious dream-enactment behaviors, risk of injury to self and bedpartner, and vivid or disruptive dreams and improving sleep quality and bedpartner sleep disruption. Safety precautions should be reviewed at each visit. Medications to reduce RBD symptoms such as melatonin, clonazepam, pramipexole, and rivastigmine should be considered for most patients. Isolated RBD confers a high lifetime risk of neurodegenerative diseases with a latency often spanning many years. A patient-centered shared decision-making approach to risk disclosure is recom...
Source: Sleep Medicine Clinics - December 26, 2023 Category: Sleep Medicine Authors: Roneil Malkani Source Type: research
A case report of atypical sleep in an ischemic stroke patient with psychiatric symptoms caused by olanzapine
Antipsychotics, tricyclic and 5-hydroxytryptamine reuptake inhibitors (SSRI) and 5-hydroxytryptamine and norepinephrine reuptake inhibitor (SNRI) antidepressants, and monoamine oxidase inhibitors can produce dream-rendering behaviors and/or dystonic deregulation during REM sleep. Acute episodes are also seen with withdrawal from alcohol or sedative-hypnotics, and the use of tricyclic and SSRI antidepressants. In this article, we present a case of olanzapine treatment of a patient with cerebrovascular disease with psychobehavioural symptoms. The patient was an elderly patient who developed psychobehavioural symptoms after a...
Source: Frontiers in Neurology - December 21, 2023 Category: Neurology Source Type: research
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases
CONCLUSIONS: Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.PMID:38062555 | DOI:10.1080/14740338.2023.2293208 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Nemanja Z Petrovi ć Ana V Pej čić Ivan R Milovanovi ć Source Type: research
Bioequivalence Study of Two Tablet Formulations of Clonazepam 2 mg: A Randomized, Open-Label, Crossover Study in Healthy Mexican Volunteers Under Fasting Conditions
ConclusionThe test and reference formulations of clonazepam 2 mg were bioequivalent and well tolerated in healthy Mexican volunteers under fasting conditions.Protocol Authorization Number213301410B0051 (Approved on April 13, 2021). (Source: Neurology and Therapy)
Source: Neurology and Therapy - December 2, 2023 Category: Neurology Source Type: research
Pharmacological treatments in panic disorder in adults: a network meta-analysis
CONCLUSIONS: In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings may be limited due to the overall low quality of the studies, with all having unclear or high risk of bias across multiple domains. Within classes, some differences emerged. For example, amongst the SSRIs paroxetine and fluoxetine seem to have stronger evidence of efficacy than sertraline. Benzodiazepines appear to have a small but significant advantage in terms of tolerability (incidence of dropouts) over other ...
Source: Cochrane Database of Systematic Reviews - November 28, 2023 Category: General Medicine Authors: Giuseppe Guaiana Nicholas Meader Corrado Barbui Simon Jc Davies Toshi A Furukawa Hissei Imai Sofia Dias Deborah M Caldwell Markus Koesters Aran Tajika Irene Bighelli Alessandro Pompoli Andrea Cipriani Sarah Dawson Lindsay Robertson Source Type: research
Pharmacological treatments in panic disorder in adults: a network meta-analysis
CONCLUSIONS: In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings may be limited due to the overall low quality of the studies, with all having unclear or high risk of bias across multiple domains. Within classes, some differences emerged. For example, amongst the SSRIs paroxetine and fluoxetine seem to have stronger evidence of efficacy than sertraline. Benzodiazepines appear to have a small but significant advantage in terms of tolerability (incidence of dropouts) over other ...
Source: Cochrane Database of Systematic Reviews - November 28, 2023 Category: General Medicine Authors: Giuseppe Guaiana Nicholas Meader Corrado Barbui Simon Jc Davies Toshi A Furukawa Hissei Imai Sofia Dias Deborah M Caldwell Markus Koesters Aran Tajika Irene Bighelli Alessandro Pompoli Andrea Cipriani Sarah Dawson Lindsay Robertson Source Type: research
Effectiveness of High-Dose Clonazepam Versus Low-Dose Clonazepam With Cognitive Behavioral Therapy in Older Adults With Moderately Severe Insomnia: A Prospective Cohort Study
Clin Ther. 2023 Nov 6:S0149-2918(23)00402-2. doi: 10.1016/j.clinthera.2023.10.010. Online ahead of print.ABSTRACTPURPOSE: To evaluate the effectiveness of high-dose clonazepam (1 mg) versus low-dose clonazepam (0.5 mg) with cognitive behavioral therapy for insomnia (CBT-i) in older adults with moderately severe insomnia.METHODS: A prospective cohort study was conducted in patients who did not respond to low-dose clonazepam for insomnia secondary to chronic medical conditions. After starting with 0.25 mg of clonazepam, their dose was increased to 0.5 mg, then to 1 mg (Group A), or to the same dose with additional CBT-i (Gro...
Source: Clinical Therapeutics - November 8, 2023 Category: Drugs & Pharmacology Authors: Karthik Sankar Natrajan Shanmugasundram Balaswetha Baskaran Deepika Anabalagan Varadharajan Sivaraman Xavier Santhiyagu Rajanandh Muhasaparur Ganesan Source Type: research
Effectiveness of High-Dose Clonazepam Versus Low-Dose Clonazepam With Cognitive Behavioral Therapy in Older Adults With Moderately Severe Insomnia: A Prospective Cohort Study
Clin Ther. 2023 Nov 6:S0149-2918(23)00402-2. doi: 10.1016/j.clinthera.2023.10.010. Online ahead of print.ABSTRACTPURPOSE: To evaluate the effectiveness of high-dose clonazepam (1 mg) versus low-dose clonazepam (0.5 mg) with cognitive behavioral therapy for insomnia (CBT-i) in older adults with moderately severe insomnia.METHODS: A prospective cohort study was conducted in patients who did not respond to low-dose clonazepam for insomnia secondary to chronic medical conditions. After starting with 0.25 mg of clonazepam, their dose was increased to 0.5 mg, then to 1 mg (Group A), or to the same dose with additional CBT-i (Gro...
Source: Clinical Therapeutics - November 8, 2023 Category: Drugs & Pharmacology Authors: Karthik Sankar Natrajan Shanmugasundram Balaswetha Baskaran Deepika Anabalagan Varadharajan Sivaraman Xavier Santhiyagu Rajanandh Muhasaparur Ganesan Source Type: research
Report Finds VA ’s Prescribing of Benzodiazepines to Homeless ‘Risky,’ ‘Inappropriate’
Homeless veterans with mental illness who use Veterans Affairs (VA) health services are less likely to receive prescriptions for benzodiazepines than those with mental illness who are not homeless, according to areport published this week inPsychiatric Services. When homeless veterans are prescribed benzodiazepines, however, they appear more likely than their peers to receive prescriptions that put them at risk for substance use disorder, overdose, and death, the study found.Drug overdose is a leading cause of death among homeless people, and benzodiazepines are often implicated in such overdose deaths, wrote Katherine Koh...
Source: Psychiatr News - November 2, 2023 Category: Psychiatry Tags: alcohol use benzodiazepines death drug use homeless overdose prescribing substance use disorder VA veterans Source Type: research
Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers
CONCLUSIONS: Our findings indicate that CD177+ neutrophils may exert systemic pathological damage contributing to the shared morbidities in KD and MIS-C. We uncovered potential regulatory drivers of CD177+ neutrophil hyperactivation and pathogenicity that may be targeted as a single therapeutic strategy for either KD or MIS-C.PMID:37905415 | DOI:10.1161/CIRCULATIONAHA.123.064734 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Jan Vincent B Beltran Fang-Ping Lin Chaw-Liang Chang Tai-Ming Ko Source Type: research
Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers
CONCLUSIONS: Our findings indicate that CD177+ neutrophils may exert systemic pathological damage contributing to the shared morbidities in KD and MIS-C. We uncovered potential regulatory drivers of CD177+ neutrophil hyperactivation and pathogenicity that may be targeted as a single therapeutic strategy for either KD or MIS-C.PMID:37905415 | DOI:10.1161/CIRCULATIONAHA.123.064734 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Jan Vincent B Beltran Fang-Ping Lin Chaw-Liang Chang Tai-Ming Ko Source Type: research
Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers
CONCLUSIONS: Our findings indicate that CD177+ neutrophils may exert systemic pathological damage contributing to the shared morbidities in KD and MIS-C. We uncovered potential regulatory drivers of CD177+ neutrophil hyperactivation and pathogenicity that may be targeted as a single therapeutic strategy for either KD or MIS-C.PMID:37905415 | DOI:10.1161/CIRCULATIONAHA.123.064734 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Jan Vincent B Beltran Fang-Ping Lin Chaw-Liang Chang Tai-Ming Ko Source Type: research
Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers
CONCLUSIONS: Our findings indicate that CD177+ neutrophils may exert systemic pathological damage contributing to the shared morbidities in KD and MIS-C. We uncovered potential regulatory drivers of CD177+ neutrophil hyperactivation and pathogenicity that may be targeted as a single therapeutic strategy for either KD or MIS-C.PMID:37905415 | DOI:10.1161/CIRCULATIONAHA.123.064734 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Jan Vincent B Beltran Fang-Ping Lin Chaw-Liang Chang Tai-Ming Ko Source Type: research
